Acquisitions /mergers/joint-ventures   AstraZeneca has agreed to acquire a 55% stake in Acerta Pharma (Oss, The Netherlands) for $4 billion, in order to acquire acalabrutinib, a treatment for cancer and autoimmune diseases, and has the option to acquire the remaining of Acerta for a further $3 billion.   Horizon Pharma (Dublin, Ireland) acquires Crealta Holdings (Glendale, […]

Acquisitions /mergers/joint-ventures   AstraZeneca is in advanced talks to acquire Acerta Pharma (Oss, The Netherlands), a privately held company focusing on immune-oncology drugs, for $5 billion. Acerta’s leading drug is acalabrutinib (ACP-196) a selective, irreversible Bruton’s tyrosine kinase inhibitor for the treatment of lymphomas and chronic lymphocytic leukemia.     Business   Novo Nordisk teams up […]

Acquisitions /mergers/joint-ventures/divestments   MundiPharma established a MundiPharma Ophthalmology business (Singapore) by acquiring Merck’s portfolio of glaucoma products in Australia, Canada, Latin America, Middle East, Africa and New Zealand. Terms of the deal were not disclosed. This transaction completes the divestiture of MSD's global ophthalmology business “as we continue to sharpen our focus in core markets and therapeutic […]

TECHNOMARKET & PRESENTING TECHNOLOGIES SESSIONS: Immunology & Oncology       Click on the image to view the presentation given by Jean-Claude Muller at Biofit 2015 the 2d December 2015   Discover our services in Marketing & Business Development: Strategic Business Development Operational Marketing & Business Development   See All News See other Biopharmaceutical News see other Pharma & […]